FORM |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||||||||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Page | |||||
PART I - FINANCIAL INFORMATION | |||||
Item 1. Financial Statements | |||||
Condensed Consolidated Statements of Operations | |||||
Condensed Consolidated Statements of Comprehensive Income (Loss) | |||||
Condensed Consolidated Balance Sheets | |||||
Condensed Consolidated Statements of Equity | |||||
Condensed Consolidated Statements of Cash Flows | |||||
Notes to Condensed Consolidated Financial Statements | |||||
Note 1. General | |||||
Note 2. Recently Issued Accounting Pronouncements | |||||
Note 3. Discontinued Operations | |||||
Note 4. Acquisitions and Investments | |||||
Note 5. Revenue | |||||
Note 6. Net Loss Per Share from Continuing Operations | |||||
Note 7. Income Taxes | |||||
Note 8. Equity | |||||
Note 9. Inventories, Net | |||||
Note 10. Debt | |||||
Note 11. Accrued Liabilities | |||||
Note 12. Financial Instruments and Fair Value Measurements | |||||
Note 13. Commitments and Contingencies | |||||
Note 14. Segment Information | |||||
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | |||||
Item 3. Quantitative and Qualitative Disclosures About Market Risk | |||||
Item 4. Controls and Procedures | |||||
PART II - OTHER INFORMATION | |||||
Item 1. Legal Proceedings | |||||
Item 1A. Risk Factors | |||||
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | |||||
Item 3. Defaults Upon Senior Securities | |||||
Item 4. Mine Safety Disclosures | |||||
Item 5. Other Information | |||||
Item 6. Exhibits | |||||
SIGNATURES |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
Net sales | $ | $ | |||||||||
Cost of sales | |||||||||||
Gross profit | |||||||||||
Selling, general and administrative expense | |||||||||||
Research and development expense | |||||||||||
Amortization of acquired intangibles | |||||||||||
Restructuring and other charges | |||||||||||
Operating loss | ( | ( | |||||||||
Interest expense, net | |||||||||||
Other income | ( | ||||||||||
Loss from continuing operations before income taxes | ( | ( | |||||||||
Income tax expense (benefit) | ( | ||||||||||
Net loss from continuing operations | ( | ( | |||||||||
Income (loss) from discontinued operations, net of taxes | ( | ||||||||||
Net income (loss) | ( | ||||||||||
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes | |||||||||||
Less: net income attributable to noncontrolling interest from discontinued operations - net of taxes | |||||||||||
Net income (loss) attributable to Enovis Corporation | $ | ( | $ | ||||||||
Net income (loss) per share - basic and diluted | |||||||||||
Continuing operations | $ | ( | $ | ( | |||||||
Discontinued operations | $ | ( | $ | ||||||||
Consolidated operations | $ | ( | $ | ||||||||
March 31, 2023 | December 31, 2022 | ||||||||||
ASSETS | |||||||||||
CURRENT ASSETS: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Trade receivables, less allowance for credit losses of $ | |||||||||||
Inventories, net | |||||||||||
Prepaid expenses | |||||||||||
Other current assets | |||||||||||
Total current assets | |||||||||||
Property, plant and equipment, net | |||||||||||
Goodwill | |||||||||||
Intangible assets, net | |||||||||||
Lease asset - right of use | |||||||||||
Other assets | |||||||||||
Total assets | $ | $ | |||||||||
LIABILITIES AND EQUITY | |||||||||||
CURRENT LIABILITIES: | |||||||||||
Current portion of long-term debt | $ | $ | |||||||||
Accounts payable | |||||||||||
Accrued liabilities | |||||||||||
Total current liabilities | |||||||||||
Long-term debt, less current portion | |||||||||||
Non-current lease liability | |||||||||||
Other liabilities | |||||||||||
Total liabilities | |||||||||||
Equity: | |||||||||||
Common stock, $ | |||||||||||
Additional paid-in capital | |||||||||||
Retained earnings | |||||||||||
Accumulated other comprehensive loss | ( | ( | |||||||||
Total Enovis Corporation equity | |||||||||||
Noncontrolling interest | |||||||||||
Total equity | |||||||||||
Total liabilities and equity | $ | $ |
Three Months Ended | ||||||||||||||
March 31, 2023 | April 1, 2022 | |||||||||||||
Net income (loss) | $ | ( | $ | |||||||||||
Other comprehensive income (loss): | ||||||||||||||
Foreign currency translation, net of tax expense of $ | ( | |||||||||||||
Unrealized gain on hedging activities, net of tax expense of $ | ||||||||||||||
Amounts reclassified from Accumulated other comprehensive loss: | ||||||||||||||
Amortization of pension and other post-retirement net actuarial gain, net of tax expense of $ | ||||||||||||||
Other comprehensive income (loss) | ( | |||||||||||||
Comprehensive loss | ( | ( | ||||||||||||
Less: comprehensive income attributable to noncontrolling interest | ||||||||||||||
Comprehensive loss attributable to Enovis Corporation | $ | ( | $ | ( |
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Noncontrolling Interest | Total | ||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||
Balance at December 31, 2022 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||
Net loss | — | — | — | ( | — | ( | |||||||||||||||||
Other comprehensive income, net of tax of $ | — | — | — | — | |||||||||||||||||||
Common stock-based award activity | — | — | — | — | |||||||||||||||||||
Balance at March 31, 2023 | $ | $ | $ | $ | ( | $ | $ |
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Noncontrolling Interest | Total | ||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||
Balance at December 31, 2021 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||
Net income | — | — | — | — | |||||||||||||||||||
Distributions to noncontrolling owners | — | — | — | — | — | ( | ( | ||||||||||||||||
Other comprehensive loss, net of tax of $ | — | — | — | — | ( | ( | ( | ||||||||||||||||
Conversion of tangible equity units into common stock | ( | — | — | — | — | ||||||||||||||||||
Common stock-based award activity | — | — | — | — | |||||||||||||||||||
Balance at April 1, 2022 | $ | $ | $ | $ | ( | $ | $ |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net (loss) income | $ | ( | $ | ||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||
Depreciation, amortization and other impairment charges | |||||||||||
Stock-based compensation expense | |||||||||||
Non-cash interest expense | |||||||||||
Deferred income tax expense | |||||||||||
Loss on sale of property, plant and equipment | |||||||||||
Changes in operating assets and liabilities: | |||||||||||
Trade receivables, net | ( | ( | |||||||||
Inventories, net | ( | ( | |||||||||
Accounts payable | |||||||||||
Other operating assets and liabilities | ( | ( | |||||||||
Net cash provided by (used in) operating activities | ( | ||||||||||
Cash flows from investing activities: | |||||||||||
Purchases of property, plant and equipment and intangibles | ( | ( | |||||||||
Proceeds from sale of property, plant and equipment | |||||||||||
Acquisitions, net of cash received, and investments | ( | ( | |||||||||
Net cash used in investing activities | ( | ( | |||||||||
Cash flows from financing activities: | |||||||||||
Payments under term credit facility | ( | ||||||||||
Proceeds from borrowings on revolving credit facilities and other | |||||||||||
Repayments of borrowings on revolving credit facilities and other | ( | ( | |||||||||
Proceeds from issuance of common stock, net | |||||||||||
Deferred consideration payments and other | ( | ( | |||||||||
Net cash provided by (used in) financing activities | ( | ||||||||||
Effect of foreign exchange rates on Cash and cash equivalents | |||||||||||
Decrease in Cash and cash equivalents | ( | ( | |||||||||
Cash and cash equivalents, beginning of period | |||||||||||
Cash and cash equivalents, end of period | $ | $ | |||||||||
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(in thousands) | |||||||||||
Net sales | $ | $ | |||||||||
Cost of sales | |||||||||||
Selling, general and administrative expense | |||||||||||
Restructuring and other charges | |||||||||||
Asbestos charges | |||||||||||
Divestiture-related expenses(1) | |||||||||||
Operating (loss) income | ( | ||||||||||
Interest expense(2) | |||||||||||
(Loss) income from discontinued operations before income taxes | ( | ||||||||||
Income tax (benefit) expense | ( | ||||||||||
(Loss) income from discontinued operations, net of taxes | $ | ( | $ |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(In thousands) | |||||||||||
Prevention & Recovery: | |||||||||||
U.S. Bracing & Support | $ | $ | |||||||||
U.S. Other P&R | |||||||||||
International P&R (1) | |||||||||||
Total Prevention & Recovery | |||||||||||
Reconstructive: | |||||||||||
U.S. Reconstructive | |||||||||||
International Reconstructive | |||||||||||
Total Reconstructive | |||||||||||
Total | $ | $ |
Three Months Ended March 31, 2023 | |||||||||||||||||||||||||||||
Balance at Beginning of Period | Charged to Expense, net | Write-Offs, Deductions and Other, net | Foreign Currency Translation | Balance at End of Period | |||||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||||||
Allowance for credit losses | $ | $ | $ | ( | $ | $ |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(In thousands, except share and per share data) | |||||||||||
Computation of Net loss per share from continuing operations - basic: | |||||||||||
Net loss from continuing operations attributable to Enovis Corporation(1) | $ | ( | $ | ( | |||||||
Weighted-average shares of Common stock outstanding – basic | |||||||||||
Net loss per share from continuing operations – basic | $ | ( | $ | ( | |||||||
Computation of Net loss per share from continuing operations - diluted: | |||||||||||
Net loss from continuing operations attributable to Enovis Corporation(1) | $ | ( | $ | ( | |||||||
Weighted-average shares of Common stock outstanding – basic | |||||||||||
Net effect of potentially dilutive securities - stock options and restricted stock units | |||||||||||
Weighted-average shares of Common stock outstanding – diluted | |||||||||||
Net loss per share from continuing operations – diluted | $ | ( | $ | ( |
Accumulated Other Comprehensive Loss Components | |||||||||||||||||
Net Unrecognized Pension and Other Post-Retirement Benefit Cost | Foreign Currency Translation Adjustment | Total | |||||||||||||||
(In thousands) | |||||||||||||||||
Balance at January 1, 2023 | $ | $ | ( | $ | ( | ||||||||||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||||
Foreign currency translation adjustment | |||||||||||||||||
Other comprehensive income (loss) before reclassifications | |||||||||||||||||
Amounts reclassified from Accumulated other comprehensive income (loss) | |||||||||||||||||
Net Other comprehensive income (loss) | |||||||||||||||||
Balance at March 31, 2023 | $ | $ | ( | $ | ( |
Accumulated Other Comprehensive Loss Components | |||||||||||||||||||||||
Net Unrecognized Pension and Other Post-Retirement Benefit Cost | Foreign Currency Translation Adjustment | Unrealized Gain on Hedging Activities | Total | ||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||
Balance at January 1, 2022 | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||||||||||
Foreign currency translation adjustment | ( | ( | |||||||||||||||||||||
Loss on long-term intra-entity foreign currency transactions | ( | ( | |||||||||||||||||||||
Gain on net investment hedges | |||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications | ( | ( | |||||||||||||||||||||
Amounts reclassified from Accumulated other comprehensive loss | |||||||||||||||||||||||
Net Other comprehensive income (loss) | ( | ( | |||||||||||||||||||||
Balance at April 1, 2022 | $ | ( | $ | ( | $ | $ | ( |
March 31, 2023 | December 31, 2022 | ||||||||||
(In thousands) | |||||||||||
Raw materials | $ | $ | |||||||||
Work in process | |||||||||||
Finished goods | |||||||||||
Less: allowance for excess, slow-moving and obsolete inventory | ( | ( | |||||||||
$ | $ |
March 31, 2023 | December 31, 2022 | ||||||||||
(In thousands) | |||||||||||
Term loan | $ | $ | |||||||||
Revolving credit facilities and other | |||||||||||
Total debt | |||||||||||
Less: current portion | ( | ||||||||||
Long-term debt | $ | $ |
March 31, 2023 | December 31, 2022 | ||||||||||
(In thousands) | |||||||||||
Accrued compensation and related benefits | $ | $ | |||||||||
Accrued taxes | |||||||||||
Accrued freight | |||||||||||
Contingent consideration - current portion | |||||||||||
Warranty liability- current portion | |||||||||||
Accrued restructuring liability - current portion | |||||||||||
Accrued third-party commissions | |||||||||||
Customer advances and billings in excess of costs incurred | |||||||||||
Lease liability - current portion | |||||||||||
Accrued interest | |||||||||||
Accrued rebates | |||||||||||
Accrued professional fees | |||||||||||
Accrued royalties | |||||||||||
Other | |||||||||||
$ | $ |
Three Months Ended March 31, 2023 | |||||||||||||||||||||||
Balance at Beginning of Period | Provisions | Payments | Balance at End of Period | ||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||
Restructuring and other charges: | |||||||||||||||||||||||
Termination benefits(1) | $ | $ | $ | ( | $ | ||||||||||||||||||
Facility closure costs and other(2) | ( | ||||||||||||||||||||||
Total | $ | $ | ( | $ | |||||||||||||||||||
Non-cash charges(2) | |||||||||||||||||||||||
Total Provisions(3) | $ |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(In thousands) | |||||||||||
Net sales: | |||||||||||
Prevention & Recovery | $ | $ | |||||||||
Reconstructive | |||||||||||
$ | $ | ||||||||||
Segment Adjusted EBITDA(1): | |||||||||||
Prevention & Recovery | $ | $ | |||||||||
Reconstructive | |||||||||||
$ | $ |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(In thousands) | |||||||||||
Loss from continuing operations before income taxes (GAAP) | $ | ( | $ | ( | |||||||
Restructuring and other charges(1) | |||||||||||
MDR and other costs(2) | |||||||||||
Strategic transaction costs | |||||||||||
Stock-based compensation | |||||||||||
Depreciation and other amortization | |||||||||||
Amortization of acquired intangibles | |||||||||||
Inventory step-up | |||||||||||
Interest expense, net | |||||||||||
Other income | ( | ||||||||||
Adjusted EBITDA (non-GAAP) | $ | $ |
Three Months Ended March 31, 2023 | |||||||||||||||||
Prevention & Recovery | Reconstructive | Total | |||||||||||||||
(Dollars in millions) | |||||||||||||||||
Net loss from continuing operations (GAAP)(1) | $ | (22.8) | |||||||||||||||
Income tax benefit | (7.1) | ||||||||||||||||
Other income | (0.7) | ||||||||||||||||
Interest expense, net | 5.7 | ||||||||||||||||
Operating loss (GAAP) | $ | (18.1) | $ | (6.8) | (25.0) | ||||||||||||
Operating loss margin | (7.2) | % | (4.4) | % | (6.1) | % | |||||||||||
Adjusted to add (deduct): | |||||||||||||||||
Restructuring and other charges(2) | 1.3 | 1.6 | 2.9 | ||||||||||||||
MDR and other costs(3) | 3.2 | 4.6 | 7.8 | ||||||||||||||
Strategic transaction costs(3) | 6.2 | 5.4 | 11.6 | ||||||||||||||
Stock-based compensation(3) | 4.1 | 2.8 | 6.9 | ||||||||||||||
Depreciation and other amortization | 5.7 | 14.2 | 20.0 | ||||||||||||||
Amortization of acquired intangibles | 23.3 | 8.8 | 32.0 | ||||||||||||||
Inventory step-up | — | 0.1 | 0.1 | ||||||||||||||
Adjusted EBITDA (non-GAAP) | $ | 25.7 | $ | 30.7 | $ | 56.4 | |||||||||||
Adjusted EBITDA margin (non-GAAP) | 10.3 | % | 19.8 | % | 13.9 | % |
Three Months Ended April 1, 2022 | |||||||||||||||||
Prevention & Recovery | Reconstructive | Total | |||||||||||||||
(Dollars in millions) | |||||||||||||||||
Net loss from continuing operations (GAAP)(1) | $ | (38.1) | |||||||||||||||
Income tax expense | 0.4 | ||||||||||||||||
Interest expense, net | 7.1 | ||||||||||||||||
Operating loss (GAAP) | $ | (14.4) | $ | (16.2) | (30.6) | ||||||||||||
Operating loss margin | (5.9) | % | (12.4) | % | (8.2) | % | |||||||||||
Adjusted to add (deduct): | |||||||||||||||||
Restructuring and other charges(2) | 2.1 | 0.8 | 3.0 | ||||||||||||||
MDR and other costs(3) | 1.7 | 0.9 | 2.6 | ||||||||||||||
Strategic transaction costs(3) | 7.6 | 4.1 | 11.7 | ||||||||||||||
Stock-based compensation(3) | 4.4 | 2.3 | 6.7 | ||||||||||||||
Depreciation and other amortization | 5.8 | 12.7 | 18.5 | ||||||||||||||
Amortization of acquired intangibles | 19.1 | 11.7 | 30.8 | ||||||||||||||
Inventory step-up | — | 5.1 | 5.1 | ||||||||||||||
Adjusted EBITDA (non-GAAP) | $ | 26.4 | $ | 21.4 | $ | 47.7 | |||||||||||
Adjusted EBITDA margin (non-GAAP) | 10.8 | % | 16.4 | % | 12.7 | % |
Three Months Ended | |||||||||||
Net Sales | Change % | ||||||||||
(Dollars in millions) | |||||||||||
For the three months ended April 1, 2022 | $ | 375.5 | |||||||||
Components of Change: | |||||||||||
Existing Businesses(1) | 35.2 | 9.4 | % | ||||||||
Acquisitions(2) | 1.1 | 0.3 | % | ||||||||
Foreign Currency Translation(3) | (5.6) | (1.5) | % | ||||||||
30.7 | 8.2 | % | |||||||||
For the three months ended March 31, 2023 | $ | 406.2 |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(Dollars in millions) | |||||||||||
Gross profit | $ | 235.1 | $ | 205.9 | |||||||
Gross profit margin | 57.9 | % | 54.8 | % | |||||||
Selling, general and administrative expense | $ | 207.2 | $ | 188.5 | |||||||
Research and development expense | $ | 18.2 | $ | 14.8 | |||||||
Operating loss | $ | (25.0) | $ | (30.6) | |||||||
Operating loss margin | (6.1) | % | (8.2) | % | |||||||
Net loss from continuing operations | $ | (22.8) | $ | (38.1) | |||||||
Net loss from continuing operations margin (GAAP) | (5.6) | % | (10.1) | % | |||||||
Adjusted EBITDA (non-GAAP) | $ | 56.4 | $ | 47.7 | |||||||
Adjusted EBITDA margin (non-GAAP) | 13.9 | % | 12.7 | % | |||||||
Items excluded from Adjusted EBITDA: | |||||||||||
Restructuring and other related charges(1) | $ | 2.9 | $ | 3.0 | |||||||
MDR and other costs | $ | 7.8 | $ | 2.6 | |||||||
Strategic transaction costs | $ | 11.6 | $ | 11.7 | |||||||
Stock-based compensation | $ | 6.9 | $ | 6.7 | |||||||
Depreciation and other amortization | $ | 20.0 | $ | 18.5 | |||||||
Amortization of acquired intangibles | $ | 32.0 | $ | 30.8 | |||||||
Inventory step-up | $ | 0.1 | $ | 5.1 | |||||||
Interest expense, net | $ | 5.7 | $ | 7.1 | |||||||
Other income | $ | (0.7) | $ | — | |||||||
Income tax expense (benefit) | $ | (7.1) | $ | 0.4 |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(Dollars in millions) | |||||||||||
Net sales | $ | 250.7 | $ | 244.8 | |||||||
Gross profit | $ | 126.9 | $ | 122.5 | |||||||
Gross profit margin | 50.6 | % | 50.0 | % | |||||||
Selling, general and administrative expenses | $ | 112.2 | $ | 108.1 | |||||||
Research and development expense | $ | 8.5 | $ | 8.3 | |||||||
Operating loss (GAAP) | $ | (18.1) | $ | (14.4) | |||||||
Operating loss margin (GAAP) | (7.2) | % | (5.9) | % | |||||||
Adjusted EBITDA (non-GAAP) | $ | 25.7 | $ | 26.4 | |||||||
Adjusted EBITDA margin (non-GAAP) | 10.3 | % | 10.8 | % |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(Dollars in millions) | |||||||||||
Net sales | $ | 155.4 | $ | 130.6 | |||||||
Gross profit | $ | 108.1 | $ | 83.4 | |||||||
Gross profit margin | 69.6 | % | 64.0 | % | |||||||
Selling, general and administrative expenses | $ | 95.0 | $ | 80.4 | |||||||
Research and development expense | $ | 9.7 | $ | 6.6 | |||||||
Operating loss (GAAP) | $ | (6.8) | $ | (16.2) | |||||||
Operating loss margin (GAAP) | (4.4) | % | (12.4) | % | |||||||
Adjusted EBITDA (non-GAAP) | $ | 30.7 | $ | 21.4 | |||||||
Adjusted EBITDA margin (non-GAAP) | 19.8 | % | 16.4 | % |
Three Months Ended | |||||||||||
March 31, 2023 | April 1, 2022 | ||||||||||
(Dollars in millions) | |||||||||||
Net cash provided by (used in) operating activities | $ | 7.5 | $ | (14.4) | |||||||
Purchases of property, plant and equipment and intangibles | (30.4) | (24.1) | |||||||||
Proceeds from sale of property, plant and equipment | — | 2.7 | |||||||||
Acquisitions, net of cash received, and investments | (3.9) | (13.8) | |||||||||
Net cash used in investing activities | (34.4) | (35.2) | |||||||||
Net borrowings (repayments) of debt | 24.9 | (7.4) | |||||||||
Proceeds from issuance of common stock, net | 0.4 | 1.2 | |||||||||
Deferred consideration payments and other | (0.8) | (4.6) | |||||||||
Net cash provided by (used in) financing activities | 24.5 | (10.8) | |||||||||
Effect of foreign exchange rates on Cash and cash equivalents | — | 2.5 | |||||||||
Increase (decrease) in Cash and cash equivalents | $ | (2.4) | $ | (57.9) |
Exhibit No. | Exhibit Description | ||||
Certificate of Amendment to Amended and Restated Certificate of Incorporation | |||||
Amended and Restated Bylaws of Enovis Corporation. | |||||
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||
101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document. | ||||
101.CAL | Inline XBRL Extension Calculation Linkbase Document. | ||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | ||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | ||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | ||||
104 | Cover Page Interactive Data File - The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 is formatted in Inline XBRL (included as Exhibit 101). | ||||
* | Incorporated by reference to Exhibit 3.01 to Enovis (formerly Colfax) Corporation’s Form 8-K (File No. 001-34045) as filed with the SEC on January 30, 2012. | ||||
** | Incorporated by reference to Exhibit 3.1 to Enovis Corporation’s Form 8-K (File No. 001-34045) as filed with the SEC on April 8, 2022. | ||||
*** | Incorporated by reference to Exhibit 3.02 to Enovis Corporation’s Form 8-K (File No. 001-34045) as filed with the SEC on December 15, 2022. |
/s/ Matthew L. Trerotola | Chief Executive Officer and Director | |||||||||||||
Matthew L. Trerotola | (Principal Executive Officer) | May 4, 2023 | ||||||||||||
/s/ Phillip B. Berry | Senior Vice President and Chief Financial Officer | |||||||||||||
Phillip B. Berry | (Principal Financial Officer) | May 4, 2023 | ||||||||||||
/s/ John Kleckner | Vice President, Controller and Chief Accounting Officer | |||||||||||||
John Kleckner | (Principal Accounting Officer) | May 4, 2023 |
1. | I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Matthew L. Trerotola | ||
Matthew L. Trerotola President and Chief Executive Officer (Principal Executive Officer) |
1. | I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Phillip B. Berry | ||
Phillip B. Berry Senior Vice President and Chief Financial Officer (Principal Financial Officer) |
/s/ Matthew L. Trerotola | ||
Matthew L. Trerotola President and Chief Executive Officer (Principal Executive Officer) |
/s/ Phillip B. Berry | ||
Phillip B. Berry Senior Vice President and Chief Financial Officer (Principal Financial Officer) |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income (loss) | $ (23,158) | $ 16,301 |
Other comprehensive income (loss): | ||
Foreign currency translation, net of tax expense | 10,584 | (53,461) |
Unrealized gain on hedging activities, net of tax expense | 0 | 9,028 |
Amounts reclassified from Accumulated other comprehensive loss: | ||
Amortization of pension and other post-retirement net actuarial gain, net of tax expense | 0 | 629 |
Other comprehensive income (loss) | 10,584 | (43,804) |
Comprehensive loss | (12,574) | (27,503) |
Less: comprehensive income attributable to noncontrolling interest | 216 | 895 |
Comprehensive loss attributable to Enovis Corporation | $ (12,790) | $ (28,398) |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Parenthetical] - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Statement of Comprehensive Income [Abstract] | ||
Foreign currency translation, tax | $ 0 | $ 338 |
Unrealized gain on hedging activities, tax | 0 | 2,711 |
Amortization of pension and other post-retirement net actuarial loss, tax | $ 0 | $ 199 |
CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] | ||
Trade receivables, allowance for doubtful accounts | $ 8,063 | $ 7,965 |
Common Stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 133,333,333 | 133,333,333 |
Common Stock, Shares, Issued | 54,493,154 | 54,228,619 |
Common Stock, Shares, Outstanding | 54,493,154 | 54,228,619 |
CONDENSED CONSOLIDATED STATEMENT OF EQUITY Statement of Stockholders' Equity [Parenthetical] - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Statement of Stockholders' Equity [Abstract] | ||
Other comprehensive income (loss), tax | $ 0 | $ 3,248 |
General |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General | General Enovis Corporation (the “Company” or “Enovis”) was previously Colfax Corporation (“Colfax”) until its separation into two differentiated, independent, and publicly traded companies on April 4, 2022 (the “Separation”). Colfax was a leading diversified technology company that provided fabrication technology and medical device products and services to customers around the world, principally under the ESAB and DJO brands. Following the completion of the Separation, the Company revised its reporting structure and conducts its business through two operating segments, “Prevention & Recovery” and “Reconstructive”. The segment results were retroactively restated to the current method the Company uses to conduct its business for all periods presented. The Separation was completed through a tax-free, pro-rata distribution of 90% of the outstanding common stock of ESAB Corporation (“ESAB”) to Colfax stockholders. To affect the Separation, Colfax distributed to its stockholders one share of ESAB common stock for every three shares of Colfax common stock held at the close of business on March 22, 2022, with the Company initially retaining 10% of the shares of ESAB common stock immediately following the Separation. Upon completion of the Separation, Colfax, which retained the Company’s specialty medical technology business, changed its name to Enovis Corporation. On April 5, 2022, the Company began trading under the stock symbol “ENOV” on the New York Stock Exchange. In connection with the Separation, ESAB issued $1.2 billion of new debt securities, the proceeds from which were used to fund a $1.2 billion cash distribution to Enovis upon separation. The distribution proceeds were used by Enovis in conjunction with $450 million of borrowings on a term loan under the new Enovis credit facility (the “Enovis Credit Agreement”) and $52.3 million of cash on hand to repay $1.4 billion of outstanding debt and accrued interest on the Company’s prior credit facility, repay $302.8 million of outstanding debt and accrued interest on its 6.375% senior notes due February 15, 2026 (the “2026 Notes”), pay a redemption premium at 103.188% of the principal amount of the 2026 Notes, and pay other fees and expenses due at closing. Additionally, on April 7, 2022, the Company completed the redemption of its 3.250% senior unsecured notes due April 2025 (the “Euro Senior Notes”) representing all of its outstanding €350 million principal Euro Senior Notes, at a redemption price of 100.813% of the principal amount. On November 18, 2022, the Company completed the divestiture of its 10% retained shares in ESAB in a tax-efficient exchange for $230.5 million of its $450 million term loan outstanding under the Enovis Credit Agreement. The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. Certain prior period amounts have been reclassified to conform to the current period presentation. The Condensed Consolidated Balance Sheet as of December 31, 2022 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim financial statements. The Condensed Consolidated Financial Statements included herein should be read in conjunction with the audited financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), filed with the SEC on March 1, 2023. The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.
|
Recently Issued Accounting Pronouncements |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Recently Issued Accounting Pronouncements | Recently Issued Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2023. There are no recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows. |
Discontinued Operations |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations | Discontinued Operations The Company’s discontinued operations include the following: (1) operating results of ESAB prior to Separation, (2) charges related to previously retained asbestos contingencies from certain divested businesses for which we did not retain an interest in the ongoing operations that were fully transferred to ESAB in conjunction with the Separation, and (3) expenses related to the Separation and the 2019 divestiture of our former air & gas handling business. The following table presents the financial results of the Company’s discontinued operations:
(1) Divestiture-related expenses include $9.8 million for the Separation for the three months ended April 1, 2022 and $0.4 million and $0.7 million for Air & Gas for the three months ended March 31, 2023 and April 1, 2022, respectively. (2) Interest expense was allocated to discontinued operations based on allocating $1.2 billion of corporate level debt to discontinued operations consistent with the dividend received from ESAB and the debt repaid at the time of the Separation. Cash provided by operating activities related to discontinued operations for the three months ended April 1, 2022 was $9.2 million. Cash used in investing activities related to discontinued operations for the three months ended April 1, 2022 was $3.2 million.
|
Acquisitions and Investments |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions and Investments | Acquisitions and Investments 2023 Acquisitions On March 31, 2023, the Company entered into a definitive agreement with Amplitude Surgical SA to acquire Novastep®, a leading player in Minimally Invasive Surgery (MIS) foot and ankle solutions. The transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the second quarter of 2023. In April 2023, the Company entered into a definitive agreement to acquire the SEAL external fixation product line from D.N.E., LLC. The transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the second quarter of 2023. 2022 Acquisitions On May 6, 2022, the Company completed a business acquisition in its Reconstructive segment of KICo Knee Innovation Company Pty Limited and subsidiaries, an Australian private company doing business as 360 Med Care, by acquiring 100% of its equity interests. 360 Med Care is a medical device distributor that bundles certain computer-assisted surgery and patient experience enhancement programs to add value to its device supply arrangements with surgeons, hospitals, and insurers. The acquisition is accounted for under the acquisition method of accounting, and accordingly, the Condensed Consolidated Financial Statements include the financial position and results of operations from the acquisition date. The Company paid $14.3 million for the acquisition, net of cash received, and recorded estimated contingent consideration at fair value of $12.8 million related to expected results over future revenue targets. The Company has allocated $16.3 million to goodwill and $18.2 million to intangible assets acquired. The 360 Med Care acquisition broadens our customer base in Australia and adds to our overall product offerings. On July 5, 2022, the Reconstructive segment of the Company acquired a controlling interest of Insight Medical Systems (“Insight”). Insight’s flagship solution, ARVIS, is an FDA-cleared augmented reality solution precisely engineered for the specific needs of hip and knee replacement surgery. The ARVIS navigation unit consists of a hands-free heads-up display worn by the surgeon which provides surgical guidance at the point of care in a streamlined, space-conserving and cost-effective manner compared to traditional robotic offerings. The acquisition is accounted for under the acquisition method of accounting as a step-acquisition, and accordingly, the Condensed Consolidated Financial Statements include the financial position and results of operations from the acquisition date. The Company made initial investments in Insight in 2020 and 2021, which were initially carried at cost. During the third quarter of 2022, the Company acquired an additional 53.7% interest in Insight for $34.2 million net of cash received, and recorded contingent consideration of $5.0 million, which is the maximum payable under the agreement based on Insight’s achievement of certain milestones related to ARVIS. The Company holds a 99.5% interest in Insight and recognized an initial $0.3 million noncontrolling equity interest in its financial statements attributed to Insight. The Company has preliminarily allocated $36.3 million to goodwill and $38.4 million to intangible assets acquired. Goodwill is primarily driven by expected synergies between ARVIS’ augmented reality surgical guidance system and our existing customer base and existing products. The Company does not expect any of the goodwill to be deductible for tax purposes. Purchase accounting procedures are ongoing and revisions to contingent consideration, intangible assets acquired, and working capital adjustments may be recorded in future periods during the measurement period. As a result of obtaining control of Insight, the Company remeasured its initial investments to fair value, resulting in a $8.8 million gain in the fourth quarter of 2022. During the three months ended April 1, 2022, the Company also completed two asset acquisitions and one investment in its Prevention & Recovery segment. The asset acquisitions broaden the Company’s product offering and distribution network. Aggregate purchase consideration for the two asset acquisitions and one investment was $18.2 million, of which $13.6 million was paid in cash and $4.6 million of deferred and contingent consideration. For further information on prior year acquisitions and investments, refer to Note 5. “Acquisitions and Investments” in the in the Company’s 2022 Form 10-K. Investments As of March 31, 2023, the balance of investments held by the Company without readily determinable fair values was $21 million. The investments are carried at cost minus impairments, if any, plus adjustments for fair value indicators from observable price changes in orderly transactions for the identical or similar investment of the same issuer. There have been no impairments or upward adjustments in the current year or since acquisition of these investments.
|
Revenue |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue | Revenue The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company’s revenue is recognized at a point in time. The Company disaggregates its revenue into the following segments:
(1) The quarter ended March 31, 2023 includes the unfavorable impact of $4.2 million of currency. Given the nature of the businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Allowance for Credit Losses The Company’s estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model further considers current conditions and reasonable and supportable forecasts using an adjustment for current and projected macroeconomic factors. A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
|
Net Loss Per Share from Continuing Operations |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss Per Share from Continuing Operations | Net Loss Per Share from Continuing Operations Net loss per share from continuing operations was computed as follows:
(1) Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $0.2 million for the three months ended March 31, 2023 and $0.3 million for the three months ended April 1, 2022. The weighted-average computation of the dilutive effect of potentially issuable shares of Common stock under the treasury stock method for the three months ended March 31, 2023 excludes 1.1 million shares underlying outstanding stock-based compensation awards, as their inclusion would be anti-dilutive. The weighted-average computation of the dilutive effect of potentially issuable shares of Common stock under the treasury stock method for the three months ended April 1, 2022 excludes 0.5 million shares underlying outstanding stock-based compensation awards, as their inclusion would be anti-dilutive.
|
Income Taxes |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes During the three months ended March 31, 2023, Loss from continuing operations before income taxes was $30.0 million, while Income tax benefit was $7.1 million. The effective tax rate was 23.7% for the three months ended March 31, 2023, which differed from the 2023 federal statutory rate of 21% mainly due to non-U.S. income taxed at lower rates, release of valuation allowance on non-U.S. attributes, and tax credits for research and development offset by other non-deductible expenses and U.S. taxation on international operations. During the three months ended April 1, 2022, Loss from continuing operations before income taxes was $37.7 million while Income tax expense was $0.4 million. The effective tax rate was (1.0)% for the three months ended April 1, 2022, which differed from the 2022 U.S. federal statutory rate of 21% mainly due to U.S. taxation on international operations and other non-deductible expenses.
|
Equity |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity | 8. Equity Share Repurchase Program In 2018, the Company’s Board of Directors authorized the repurchase of shares of the Company’s Common stock from time-to-time on the open market or in privately negotiated transactions. No repurchases of the Company’s Common stock have been made under this plan since the third quarter of 2018. As of March 31, 2023, the remaining stock repurchase authorization provided by the Board of Directors was $100 million. The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. There is no term associated with the remaining repurchase authorization. Accumulated Other Comprehensive Loss The following tables present the changes in the balances of each component of Accumulated other comprehensive loss including reclassifications out of Accumulated other comprehensive loss for the three months ended March 31, 2023 and April 1, 2022. All amounts are net of tax and noncontrolling interest, if any.
|
Inventories, Net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories, Net | Inventories, Net Inventories, net consisted of the following:
|
Debt |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | Debt Long-term debt consisted of the following:
Debt Redemptions In conjunction with the Separation, which occurred on April 4, 2022, the Company repaid all obligations under its previous credit agreement and entered into a new credit agreement (the “Enovis Credit Agreement”) with certain of its existing bank lenders. Additionally, on April 7, 2022, after the completion of the Separation, the Company completed the redemptions of its 3.25% Euro Senior Notes due 2025 and its 6.375% Senior Notes due 2026. As a result of these changes, the Company recorded Debt extinguishment charges of $20.1 million in the second quarter of 2022, comprised of $12.7 million in redemption premiums and $7.4 million in noncash write-offs of original issue discount and deferred financing fees. Enovis Term Loan and Revolving Credit Facility The Enovis Credit Agreement became effective on April 4, 2022 and consists of a $900 million revolving credit facility (the “Revolver”) with an April 4, 2027 maturity date and a term loan with an initial aggregate principal amount of $450 million and an April 4, 2023 maturity date (the “Enovis Term Loan”). The Revolver contains a $50 million swing line loan sub-facility. Certain U.S. subsidiaries of the Company guarantee the obligations under the Enovis Credit Agreement. On November 18, 2022, the Company completed an exchange with a lender under the Enovis Credit Agreement of 6,003,431 shares of common stock of ESAB, representing all of the retained shares in ESAB following the Separation, for $230.5 million of the $450.0 million in term loan outstanding under the Credit Agreement, net of cost to sell. On March 1, 2023, the Company extinguished the remaining outstanding balance on the Enovis Term Loan with borrowings on the Revolver. The Enovis Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments, or pay dividends. In addition, the Enovis Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum total leverage ratio of not more than 4.00:1.00, stepping down to 3.75:1.00 for the fiscal quarter ending June 30, 2023 and to 3.50:1.00 for the fiscal quarter ending June 30, 2024, and (ii) a minimum interest coverage ratio of 3.00:1:00. The Enovis Credit Agreement contains various events of default (including failure to comply with the covenants under the Enovis Credit Agreement and related agreements), and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Enovis Credit Agreement. As of March 31, 2023, the Company was in compliance with the covenants under the Enovis Credit Agreement. As of March 31, 2023, the weighted-average interest rate of borrowings under the Enovis Credit Agreement was 6.02%, excluding accretion of original issue discount and deferred financing fees, and there was $615 million available on the Revolver. The Company has $4.3 million in deferred financing fees recorded in conjunction with the Enovis Credit Agreement as of March 31, 2023, which are being accreted to Interest expense, net primarily using the effective interest method over the life of the facility. Euro Senior Notes The Company had senior unsecured notes with an aggregate principal amount of €350 million due in May 2025, with an interest rate of 3.25%. The Euro Senior Notes were redeemed on April 7, 2022 at a 100.813% redemption premium after the completion of the Separation. Tangible Equity Unit (“TEU”) Amortizing Notes The Company previously had 6.50% TEU amortizing notes at an initial principal amount of $15.6099 per note with equal quarterly cash installments of $1.4375 per note representing a payment of interest and partial payment of principal. The Company paid $6.5 million of principal on the TEU amortizing notes in the three months ended April 1, 2022. The final installment payment was made on January 15, 2022. 2026 Notes The Company had senior notes with a remaining principal amount of $300 million, which were due on February 15, 2026 and had an interest rate of 6.375%. The 2026 Notes were redeemed on April 7, 2022 at a 103.188% redemption premium after the completion of the Separation. Other Indebtedness In addition to the debt agreements discussed above, the Company is party to overdraft facilities with a borrowing capacity of $30.0 million. Total letters of credit and surety bonds of $7.1 million were outstanding as of March 31, 2023.
|
Accrued Liabilities |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities | Accrued Liabilities Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following:
Accrued Restructuring Liability The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Condensed Consolidated Balance Sheets is as follows:
(1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of facilities, site cost structures, and product lines. (3) For the three months ended March 31, 2023, $1.3 million and $1.6 million of the Company’s total provisions were related to the Prevention & Recovery and Reconstructive segments, respectively. Restructuring and other charges includes $0.3 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2023.
|
Financial Instruments and Fair Value Measurements |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Financial Instruments and Fair Value Measurements [Abstract] | |
Financial Instruments and Fair Value Measurements | Financial Instruments and Fair Value MeasurementsThe carrying values of financial instruments, including trade receivables, other receivables and accounts payable, approximate their fair values due to their short-term maturities. The estimated fair value of the Company’s debt, which was $285.0 million as of March 31, 2023, was based on current interest rates for similar types of borrowings and is in Level Two of the fair value hierarchy. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. As of March 31, 2023, the Company held $22.2 million in Level Three liabilities arising from contingent consideration related to acquisitions. The fair value of the contingent consideration liabilities is determined using unobservable inputs and the inputs vary based on the nature of the purchase agreements. These inputs can include the estimated amount and timing of projected cash flows, the risk-adjusted discount rate used to present value the projected cash flows, and the probability of the acquired company attaining certain targets stated within the purchase agreements. A change in these unobservable inputs to a different amount might result in a significantly higher or lower fair value measurement at the reporting date due to the nature of uncertainty inherent to the estimates. During the three months ended March 31, 2023 the Company recorded a reduction in contingent consideration of $0.8 million due to a final agreement on the payout from an acquisition in 2020. The gross range of outcomes for contingent consideration arrangements that have a fixed limit on the maximum payout is zero to $10.9 million. There are two contingent consideration arrangements that have no limits and are based on a percentage of sales in excess of a benchmark over a three-year period and five-year period, respectively. There were no transfers in or out of Level One, Two or Three during the three months ended March 31, 2023. Deferred Compensation Plans The Company maintains deferred compensation plans for the benefit of certain employees and non-executive officers. As of March 31, 2023 and December 31, 2022 the fair value of these plans were $12.8 million and $10.3 million, respectively. These plans are deemed to be Level Two within the fair value hierarchy. Foreign Currency Contracts As of March 31, 2023 and December 31, 2022, the Company had foreign currency contracts related to purchases and sales with notional values of $3.0 million and $0.8 million, respectively. During the three months ended March 31, 2023, the Company recognized an unrealized gain of $0.1 million on its Condensed Consolidated Statements of Operations related to its derivative instruments.
|
Commitments and Contingencies |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies The Company is involved in various pending legal proceedings arising out of the ordinary course of the Company’s business. None of these legal proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, management of the Company believes that either it will prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded as incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these legal proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company. For further description of the Company’s litigation and contingencies, reference is made to Note 18, “Commitments and Contingencies” in the Notes to Consolidated Financial Statements in the Company’s 2022 Form 10-K.
|
Segment Information |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information | Segment Information The Company conducts its continuing operations through the Prevention & Recovery and Reconstructive operating segments, which also represent the Company’s reportable segments. ▪Prevention & Recovery - a leader in orthopedic solutions and recovery sciences, providing devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. •Reconstructive - an innovation market-leader positioned in the fast-growing surgical implant business, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The Company’s management, including the chief operating decision maker, evaluates the operating results of each of its reportable segments based upon Net sales and Adjusted EBITDA, which excludes the effect of restructuring and certain other charges, MDR and other costs, strategic transaction costs, stock-based compensation, depreciation and other amortization, acquisition-related intangible asset amortization, and inventory step-up charges from the results of the Company’s operating segments. The Company’s segment results were as follows:
(1) The following is a reconciliation of Loss from continuing operations before income taxes to Adjusted EBITDA:
(1) Restructuring and other charges includes $0.3 million and $0.5 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and April 1, 2022, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Devices Regulation. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
|
Recently Issued Accounting Pronouncements (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting | The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. Certain prior period amounts have been reclassified to conform to the current period presentation. The Condensed Consolidated Balance Sheet as of December 31, 2022 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim financial statements. |
Use of Estimates | The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates. |
New Accounting Pronouncements | There are no recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows. |
Discontinued Operations and Disposal Groups (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Results of Discontinued Operations | The following table presents the financial results of the Company’s discontinued operations:
(1) Divestiture-related expenses include $9.8 million for the Separation for the three months ended April 1, 2022 and $0.4 million and $0.7 million for Air & Gas for the three months ended March 31, 2023 and April 1, 2022, respectively. (2) Interest expense was allocated to discontinued operations based on allocating $1.2 billion of corporate level debt to discontinued operations consistent with the dividend received from ESAB and the debt repaid at the time of the Separation.
|
Revenue (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Revenue by Major Customers by Reporting Segments | The Company disaggregates its revenue into the following segments:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financing Receivable, Allowance for Credit Loss | A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
|
Net Loss Per Share from Continuing Operations (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Loss Per Share from Continuing Operations | Net loss per share from continuing operations was computed as follows:
(1) Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $0.2 million for the three months ended March 31, 2023 and $0.3 million for the three months ended April 1, 2022.
|
Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss |
|
Inventories, Net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory | Inventories, net consisted of the following:
|
Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Debt | Long-term debt consisted of the following:
|
Accrued Liabilities (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Liabilities | Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Restructuring Liability | A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Condensed Consolidated Balance Sheets is as follows:
(1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of facilities, site cost structures, and product lines. (3) For the three months ended March 31, 2023, $1.3 million and $1.6 million of the Company’s total provisions were related to the Prevention & Recovery and Reconstructive segments, respectively. Restructuring and other charges includes $0.3 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2023.
|
Segment Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment | The Company’s segment results were as follows:
(1) The following is a reconciliation of Loss from continuing operations before income taxes to Adjusted EBITDA:
(1) Restructuring and other charges includes $0.3 million and $0.5 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and April 1, 2022, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Devices Regulation. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
|
Discontinued Operations - Narratives (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations $ in Millions |
3 Months Ended |
---|---|
Apr. 01, 2022
USD ($)
| |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |
Cash (used in) provided by operating activities, discontinued operations | $ 9.2 |
Cash used in investing activities, discontinued operations | $ (3.2) |
Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Revenue from contract with customer | $ 406,151 | $ 375,457 |
Prevention and Recovery | ||
Revenue from contract with customer | 250,740 | 244,835 |
Prevention and Recovery | Bracing and Support | U.S. | ||
Revenue from contract with customer | 104,375 | 103,035 |
Prevention and Recovery | Other Prevention and Recovery | U.S. | ||
Revenue from contract with customer | 62,347 | 57,714 |
Prevention and Recovery | Prevention and Recovery | International | ||
Revenue from contract with customer | 84,018 | 84,086 |
Foreign currency loss | 4,200 | |
Reconstructive Segment | ||
Revenue from contract with customer | 155,411 | 130,622 |
Reconstructive Segment | Surgical | U.S. | ||
Revenue from contract with customer | 103,492 | 88,479 |
Reconstructive Segment | Surgical | International | ||
Revenue from contract with customer | $ 51,919 | $ 42,143 |
Revenue - Allowance for Credit Loss Rollforward (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
| |
Financing Receivable, Allowance for Credit Loss [Roll Forward] | |
Balance at Beginning of Period | $ 7,965 |
Charged to Expense, net | 528 |
Write-Offs, Deductions and Other, net | (463) |
Foreign Currency Translation | 33 |
Balance at End of Period | $ 8,063 |
Net Loss Per Share from Continuing Operations (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Earnings Per Share [Abstract] | ||
Net loss from continuing operations attributable to Parent | $ (23,038) | $ (38,322) |
Weighted-average shares of Common stock outstanding - basic (in shares) | 54,325,396 | 53,872,007 |
Net loss per share from continuing operations-basic (in usd per share) | $ (0.42) | $ (0.71) |
Net effect of potentially dilutive securities - stock options and restricted stock units (in shares) | 0 | 0 |
Weighted-average shares of Common stock outstanding - diluted (in shares) | 54,325,396 | 53,872,007 |
Net loss per share from continuing operations - diluted (in usd per share) | $ (0.42) | $ (0.71) |
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes | $ 192 | $ 267 |
Net Loss Per Share from Continuing Operations - Narrative (Details) - shares shares in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Earnings Per Share [Abstract] | ||
Antidilutive securities excluded from computation of earnings per share | 1.1 | 0.5 |
Income Taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Apr. 01, 2022 |
|
Income Tax Disclosure [Abstract] | ||
Loss from continuing operations before income taxes | $ (29,959) | $ (37,691) |
Income tax benefit | $ 7,113 | $ (364) |
Effective tax rate | 23.70% | (1.00%) |
Equity Textual (Details) |
Mar. 31, 2023
USD ($)
|
---|---|
Equity [Abstract] | |
Stock repurchase program, authorized amount | $ 100,000,000 |
Inventories, Net (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 100,095 | $ 100,038 |
Work in process | 33,936 | 28,164 |
Finished goods | 363,473 | 357,143 |
Inventory, gross | 497,504 | 485,345 |
Less: allowance for excess, slow-moving and obsolete inventory | (58,547) | (58,702) |
Inventories, net | $ 438,957 | $ 426,643 |
Debt - Components (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Debt Instrument [Line Items] | ||
Total Debt | $ 285,000 | $ 259,279 |
Less: current portion | 0 | (219,279) |
Long-term debt | 285,000 | 40,000 |
Term loan | ||
Debt Instrument [Line Items] | ||
Total Debt | 0 | 219,279 |
Revolving credit facilities and other | ||
Debt Instrument [Line Items] | ||
Total Debt | $ 285,000 | $ 40,000 |
Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Accrued Liabilities [Abstract] | ||
Accrued compensation and related benefits | $ 47,252 | $ 51,384 |
Accrued taxes | 16,980 | 13,676 |
Accrued freight | 4,155 | 3,955 |
Contingent consideration - current portion | 7,841 | 8,812 |
Warranty liability- current portion | 2,826 | 2,804 |
Accrued restructuring liability - current portion | 944 | 1,090 |
Accrued third-party commissions | 23,945 | 24,958 |
Customer advances and billings in excess of costs incurred | 3,919 | 3,560 |
Lease liability - current portion | 23,116 | 24,281 |
Accrued interest | 599 | 2,921 |
Accrued rebates | 7,211 | 13,715 |
Accrued professional fees | 13,708 | 15,670 |
Accrued royalties | 5,996 | 5,777 |
Other | 39,262 | 37,689 |
Accrued liabilities | $ 197,754 | $ 210,292 |
E:X(8L(^-H :PQ[V
MOAF,XR"V8(\;[+$3^Q=%< PWG/]H-,[3'F;7- -
M>X <6 $C'41NY2PZ:8%\ &B8FY+O:PEH4#'90+[<%XF7X[VT+KV7M=!4:
MDB=^DK]C3]4> 4P\BLAG>4
M?[%RMA3ODL_)^V0H/GVZ_'/% _].GT#=5APSY*;[(4KQMU D7XIE6]^R5\G0
MIH'E+Z0-)5US(X#RG*,'K1^O+JWX:)1")@Q,YUVM^)NP%9]TJ5D!K$54O,ZT
M=%IYH!*IJXDG"BTIQAJ[%9M$>S-+H=H9Y<7L>"RN(>E2.C44RVV3.5HV&8]_
M)&O(5H67T*LY^QYM=V\C!56*4F5<-IFZTZD2F889>EDC!PB/#%!KLD)YD2H7
MT)W9J!KR#J7W6*O(E5@KY%8%KRDJ!PUPPLK5
M86$O/&)OJJD&/ &:B 49BPR/76+.PQK(-8]%!N3[:*:TQ,S^8?->:;UEMVZ.
M^X7*:0P#!PTKD&MPAG__Y;>]?VS4/\C8GB-:E2-:3=:'=UB=6,GX)!5*G=K8
MEB;:A0E3B];#LR#THV[?7>_RJ(OY[=#S*ZD]@%$%,&J,U+U.0))X+T1[@"]L
MB*./C,\'&=NCWZ[HMQOC@_41JQ_'\B,E\/@7P9SD*J6F[GXF'(H$UO2%P MV
M$P4V9Y1?B';CXD7=UD'TZE)G4=AJ'PE?I\+?:<3_S+&AI>PWS,D2&QG!;I'
M?,GXLNP:3#-0[R72J4'T#DC4)7I>T+53Z%84NHT9.,K$BFN%C3).J5)LP9#,
M0HJ,C.)XE:TP&+@A+'EJ\M.:GMV/3,\/,K;GFU[EFUYC>-$W4K/?13J: .;;
MH0*[SM8CN5#Z3()FLJRW)M(8^165C*9%3KPW^KT_1K\NT0YZ]N#[WEM3]AHI
M_K$ 6;NK]ZXS9Q$[:X5=KW4$],XDX3>"'M?RT(K2KW_>#Z).#:9%+NA$7G@$
M9O &,VB$>0-X0.R^I5I+-EMI.DN!:$&XP'VNI4A34SP8UX#IK*VT@AK
Z.W5*!BAC7C@^T1_DD_OQ=$A5O07R20O?Z.GHZTS0M$^US(]
M-@8%:9Q5?_FWXT2<-,!N3P-R;$"^MP$]-J"EHY6RTJT%UWQZJ>034H4U]%8\
ME'-3M@9OXJQ8QK56\&T,[?1T_O%FL;Q9+Q<(GM8?KU>+V1V\O)M=SV[F2[1^
MOUS>K=$9^KQ>H-_>_([>H#A#=UNYSWFVR2\G&C04/4VBXWCOJO%(SW@?N#I'
M%(\1<0BU-)\/-U^(J&Y.VLTGX'GM/JG=)V5_M*>_V7H-_MG
]08MN0)HC)L *.48C=0
M*MM@Z#K$"926(#+8]65J$4\!C$V1B>,$YF8+;A4C>)1D= 98,>T0.PXOL1QDBDHH9*W1
MX+W^Q@=36:/;A-U#$-1W ]I[^_4V[Z;Z-;S;C?*"-EJ25E@(=#BX/(_ =?NF
M,]@V8<;7EF5CA&,I*QJ=#Y#[PEK>&SY!O_33OU!+ P04 " #%,J16;'AE
MBN<$ C# &0 'AL+W=O3(AK',SO77GX
M#H+(-K)//(X7'MVHD*X/O(9WO2SI*.YKY=@W>+.6F".7U"F,[3M!@NIJ(UVV
MYT"3Q+0&[B"7D<,J>;+MC5U1H]\+7_+45>*H=Q6,]I+SA;<7S/7Q5KA[V]VI
M+^)5\FYYO) '4' T\*)0*VP=)Z^/!L+%2^[X$&S%%\L8B]'+^"?-],K1 GRG
MR[?V@11T_]-P\5]02P,$% @ Q3*D5NXR#D?+!@ B \ !D !X;"]W
M;W)K